Anti-Angiogenic Chemotherapy

Title Average Ratingsort ascending
Combining agents that target the tumor microenvironment improves the efficacy of anticancer therapy. 90.00%
Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor acti 90.00%
Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. 90.00%
Artesunate in the treatment of metastatic uveal melanoma--first experiences. 90.00%
Artemisinin derivates in the treatment of Cancer 90.00%
Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in mice. 90.00%
Systems biology: a therapeutic target for tumor therapy. 86.67%
A phase II trial of sunitinib (S) in previously-treated pancreas adenocarcinoma (PAC), CALGB 80603. 80.00%
Willmar Schwabe Award 2006: antiplasmodial and antitumor activity of artemisinin--from bench to bedside. 80.00%
The antifungal drug itraconazole inhibits vascular endothelial growth factor receptor 2 (VEGFR2) glycosylation, trafficking and 80.00%
Clinical and Pharmacodynamic Evaluation of Metronomic Cyclophosphamide, Celecoxib, and Dexamethasone in Advanced Hormone-refract 80.00%
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. 80.00%
Phase II Study of Dasatinib in Patients with Metastatic Castration-Resistant Prostate Cancer. 80.00%
Tetrathiomolybdate-associated copper depletion decreases circulating endothelial progenitor cells in women with breast cancer at high risk of relapse 80.00%
Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. 80.00%
Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer 80.00%
Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: Phase I study. 80.00%
Bevacizumab for recurrent ependymoma. 80.00%
Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer. 80.00%
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. 80.00%
Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patient 80.00%
Durable responses with the metronomic rituximab and thalidomide plus prednisone, etoposide, procarbazine, and cyclophosphamide r 70.00%
Phase I study of sunitinib malate continuously dosed and standard-infusion gemcitabine in solid tumors. 70.00%
Synergistic cytotoxicity of artemisinin and sodium butyrate on human cancer cells. 70.00%
Angiogenesis and cancer: A cross-talk between basic science and clinical trials (the "do ut des" paradigm). 70.00%
Antiangiogenic (metronomic) chemotherapy for brain tumors: current and future perspectives. 70.00%
A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses 70.00%
Artesunate inhibits angiogenesis and downregulates vascular endothelial growth factor expression in chronic myeloid leukemi 70.00%
Hypoxia-inducible factor-1alpha modulation in combination with anti-angiogenic therapy. 60.00%
Anti-angiogenic therapies for metastatic colorectal cancer. 60.00%
Final results of a pharmacokinetic (PK) and pharmacodynamic (PD) phase I trial of ARQ 197 incorporating dynamic contrast........ 60.00%
Antiangiogenic drugs currently used for colorectal cancer: what other pathways can we target to prolong responses? 60.00%
Experimental therapy of hepatoma with artemisinin and its derivatives: in vitro and in vivo activity, chemosensitization, and m 60.00%
Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. 60.00%
Complete remission of psoriasis following bevacizumab therapy for colon cancer. 60.00%
Metronomic administration of ibandronate and its anti-angiogenic effects in vitro. 60.00%
A case of metronomic chemotherapy as an alternative cancer therapy for palliation 60.00%
Low dose carboplatin combined with angiostatic agents prevents metastasis in human testicular germ cell tumor xenografts. 55.00%
Final analysis of a phase II trial using sorafenib for metastatic castration-resistant prostate cancer. 50.00%
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal 50.00%
Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. 50.00%
Chemoradiotherapy in malignant glioma: standard of care and future directions. 50.00%
Inhibitive effect of artemether on tumor growth and angiogenesis in the rat C6 orthotopic brain gliomas model. 50.00%
Case report of a pituitary macroadenoma treated with artemether. 50.00%
Role of everolimus in the treatment of renal cell carcinoma. 50.00%
Novel anti-angiogenic therapies for malignant gliomas. 50.00%
Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplat 40.00%
Circulating tumor and endothelial cells as pharmacodynamic biomarkers in a phase I clinical trial of intravenous bevacizumab.... 40.00%
Combination antiangiogenic therapy: increased efficacy in a murine model of Wilms tumor. 40.00%
A pilot study of adjuvant bevacizumab and chemotherapy after neoadjuvant chemotherapy for high-risk breast cancer. 0.00%